PDH has received research funding from AstraZeneca; and in the past year had received consulting fees from Abbott Labs, Cypress Bioscience, Eli Lilly & Co., Merck, Schering-Plough (now part of Merck), Sepracor Pharma, Solvay Pharma (now part of Abbott Laboratories), and Wyeth Pharma (now part of Pfizer). CRB has received consulting fees and has participated in advisory board meetings for Abbott Pharmaceuticals. CAD, BTM, PSW, MHT, JRL, JAM, AEP, and TLP have no conflicts of interest to report.
Social competence and observer-rated social functioning in bipolar disorder
Version of Record online: 22 DEC 2010
© 2010 John Wiley and Sons A/S
Volume 12, Issue 8, pages 843–850, December 2010
How to Cite
Depp, C. A., Mausbach, B. T., Harvey, P. D., Bowie, C. R., Wolyniec, P. S., Thornquist, M. H., Luke, J. R., McGrath, J. A., Pulver, A. E. and Patterson, T. L. (2010), Social competence and observer-rated social functioning in bipolar disorder. Bipolar Disorders, 12: 843–850. doi: 10.1111/j.1399-5618.2010.00880.x
- Issue online: 22 DEC 2010
- Version of Record online: 22 DEC 2010
- Received 15 June 2010, revised and accepted for publication 7 October 2010
- bipolar disorder;
- social functioning
Depp CA, Mausbach BT, Harvey PD, Bowie CR, Wolyniec PS, Thornquist MH, Luke JR, McGrath JA, Pulver AE, Patterson TL. Social competence and observer-rated social functioning in bipolar disorder. Bipolar Disord 2010: 12: 843–850. © 2010 The Authors. Journal compilation © 2010 John Wiley & Sons A/S.
Objective: Impairment in social functioning appears to be common in bipolar disorder, although estimates have been derived largely from self-report measures. We examined performance-based and observer-based ratings of social competence and functioning and assessed the contribution of symptoms and neurocognitive ability to social functioning in bipolar disorder.
Methods: In this cross-sectional study, 164 subjects with bipolar disorder were administered the performance-based Social Skills Performance Assessment (SSPA), rated by an informant on the Specific Level of Functioning (SLOF)–Interpersonal subscale, received clinical ratings of depression and manic symptoms, and performed neurocognitive tests. We assessed the proportion of patients exhibiting social deficits and examined the associations between composite measures of neurocognitive ability, depression and manic symptoms, and SSPA scores with informant-rated, real-world social functioning.
Results: Mean age of the sample was 47.6 years (SD = 14.1). Subjects were experiencing, on average, mild levels of depression and minimal manic symptoms. A total of 29% exhibited norm-referenced impairment on the SSPA, and 64% registered at least one impairment on SLOF items; unemployed subjects had lower SSPA and SLOF ratings. Neurocognitive performance correlated with both performance-based and observer-rated social functioning, whereas depressive and manic symptoms correlated only with observer-rated social impairments. In multivariate models, depression was the most potent association with social functioning, and impairment in social competence (i.e., capacity) increased the strength of the relationships between depression and neurocognitive impairment and social functioning (i.e., real-world functioning).
Conclusions: Our study confirmed the negative relationship of bipolar depression with social functioning. A subgroup of outpatients with bipolar disorder has impaired social competence, which, when present, worsened the impact of depression and cognitive impairment on social functioning.